

CMP: ₹1130

Target ₹ 1340 (19%)

Target Period: 12 months

July 24, 2026

US weakness, one-offs hurt numbers but outlook promising...

About the stock: Dr Reddy's (DRL) business encompasses generic formulations sales across US, Europe, RoW markets and branded generics in India and Russia CIS. The business also comprises of API sales under the head PSAL.

- Revenue breakup FY26: US (~34%), India (~19%), Russia and CIS (~13%), Europe (~8%), RoW (~7%), PSAL (~11%) and NRT portfolio (~8%).
- It owns 14 formulation facilities, 9 API manufacturing facilities, one biologics facility and several R&D centres across the globe.

Result Performance & Investment Rationale:

- Q1FY27 – Performance continues to improve:** Q1FY27 revenues de-grew 5.5% YoY to ₹ 8099.8 crore, pulled down significantly by the US business which de-grew 35% YoY to ₹2205 crore and PSAL which grew 4.1% YoY to ₹852 crore. The US business declined primarily on account of lower gRevlimid sales. Other key geographies performed relatively better- Europe grew 13% YoY to ₹1444 crore (Nicotine Replacement Therapy portfolio in Europe de-grew 1% YoY to ~₹660 crore), India Business grew 17% YoY to ₹1717.7 crore, Russia and Other CIS business grew 24% YoY to ₹1120 crore and RoW market grew 42% YoY to ₹710 crore. The company undertook impairments and provisions (related to Semaglutide impurities) during the quarter aggregating to ~₹239 crore which led to EBITDA de-growth of ~60% YoY to ₹ 861 crore with margins dwindling by 1472 bps to 10.6%. GPM for the quarter also declined by 904 bps to 58.2%. Excluding the one-time impairment and provisions the EBITDA margins for the quarter stood at ~14%. During the quarter the company launched 43 products across geographies.
- Niche launches, in-licensing deals to fuel growth ahead:** Excluding US performance which obviously got impacted by lower gRevlimid sales, the overall print was decent. The pressure on margins (due to Middle east freight and logistical costs) is transient. The management has firm plans for GLP 1 opportunities, biosimilars and innovative products to be launched across the world (90+ countries). The idea is to fill the possible void after the complete genericization of gRevlimid (double digit growth guidance ex-US). R&D spend is expected to remain at ~7-8% of revenues, while base EBITDA margins are projected at ~20% despite the halt in Semaglutide supplies. Management is targeting sales resumption of the Semaglutide supplies by November 2026. The company is also increasing focus on branded generics which now account for ~42% of the overall revenues. Calibrated focus and subsequent launches in the complex space is crucial for the company to achieve the aspirational EBITDA and ROCE targets of around 25%. Overall, we look beyond the quarterly gyrations and towards larger picture. The company is also looking to utilise the ~₹ 3000 crore cash pile for productive acquisitions.

Rating and Target Price: We maintain our BUY rating with target price is ₹ 1340 based on 22x FY28E EPS of ₹60.7

BUY


Dr.Reddy's

Particulars**Particular**

Market Capitalisation	₹94242 crore
Debt (FY26)	₹7734 crore
Cash (FY26)	₹1537 crore
EV	₹100439 crore
52-week H/L	1415/1080
Equity capital	₹83.4 crore
Face value	₹1

Shareholding pattern

	Sep-25	Dec-25	Mar-26	Jun-26
Promoters	26.6	26.6	26.6	26.6
FII	24.7	22.3	21.1	20.7
DII's	28.0	30.4	30.7	31.8
Others	20.7	20.6	21.5	21.0

Price Chart**Key risks**

- Slower ramp up in new launches especially in the US
- Increasing intangible component of the balance sheet due to licensing deals

Research Analyst

Siddhant Khandekar
siddhant.khandekar@icicisecurities.com

Shubh Mehta
shubh.mehta@icicisecurities.com

Vedant Nilekar
vedant.nilekar@icicisecurities.com

Key Financial Summary

Key Financials (₹ crore)	FY23	FY24	FY25	FY26	3 year CAGR (FY23-26)	FY27E	FY28E	2 year CAGR (FY26-28E)
Revenues	24669.7	28011.1	32648.0	33700.2	11.0	34335.2	39364.2	8.1
EBITDA	6348.9	7924.7	8481.9	6805.3	2.3	5612.5	8463.3	11.5
EBITDA Margins (%)	25.7	28.3	26.0	20.2		16.3	21.5	
Adjusted PAT	4470.2	5563.2	5707.5	4144.2	-2.5	3413.8	5064.9	10.6
EPS (Adjusted)	53.6	66.7	68.4	49.7		40.9	60.7	
PE (x)	20.9	16.9	16.5	22.7		27.6	18.6	
RoE (%)	19.2	19.7	17.0	10.9		8.4	11.2	
RoCE (%)	21.2	21.8	18.4	10.0		7.6	12.9	

Source: Company, ICICI Direct Research

Exhibit 1: Quarterly Summary

₹ Crore	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26	Q4FY26	Q1FY27	YoY (%)	QoQ (%)
Total Operating Income	7113.8	7696.1	8038.3	8385.2	8528.4	8572.1	8828.3	8753.4	7546.4	8099.8	-5.5	7.3
Raw Material Expenses	2092.1	2181.7	2366.7	2581.5	2850.0	2807.5	3123.7	3095.3	3212.7	3385.1	20.6	5.4
% of Revenues	29.4	28.3	29.4	30.8	33.4	32.8	35.4	35.4	42.6	41.8	904 bps	-78 bps
Gross Profit	5021.7	5514.4	5671.6	5803.7	5678.4	5764.6	5704.6	5658.1	4333.7	4714.7	-18.2	8.8
Gross Profit Margins (%)	70.6	71.7	70.6	69.2	66.6	67.2	64.6	64.6	57.4	58.2	-904 bps	78 bps
Employee expenses	1283.6	1413.7	1399.2	1366.5	1400.6	1503.5	1452.1	1588.5	1446.8	1651.6	9.9	14.2
% of Revenues	18.0	18.4	17.4	16.3	16.4	17.5	16.4	18.1	19.2	20.4	285 bps	122 bps
Other expenses	1906.9	1970.3	2195.8	2160.2	2279.9	2087.5	2175.3	2155.1	2246.9	2201.7	5.5	-2.0
% of Revenues	26.8	25.6	27.3	25.8	26.7	24.4	24.6	24.6	29.8	27.2	283 bps	-259 bps
Total Expenditure	5282.6	5565.7	5961.7	6108.2	6530.5	6398.5	6751.1	6838.9	6906.4	7238.4	13.1	4.8
% of Revenues	74.3	72.3	74.2	72.8	76.6	74.6	76.5	78.1	91.5	89.4	1472 bps	-215 bps
EBITDA	1831.2	2130.4	2076.6	2277.0	1997.9	2173.6	2077.2	1914.5	640.0	861.4	-60.4	34.6
EBITDA Margins (%)	25.7	27.7	25.8	27.2	23.4	25.4	23.5	21.9	8.5	10.6	-1472 bps	215 bps
Total Depreciation	367.7	381.1	397.0	471.4	454.7	476.1	504.6	521.0	557.1	536.6	12.7	-3.7
Interest	59.3	59.8	75.7	81.7	65.6	83.0	90.7	94.4	105.7	125.5	51.2	18.7
Share of profit/ (loss) of equity accounted investees	-3.5	-5.9	-6.1	-4.2	-5.5	-0.2	-6.3	-2.3	-4.6	0.8		
Other income	197.5	187.2	307.4	150.2	522.1	290.3	323.9	268.8	475.4	354.7		
EBT	1605.2	1882.6	1917.4	1878.3	2005.2	1905.0	1812.1	1570.2	457.2	553.2	-71.0	21.0
Total Tax	295.4	490.2	575.5	470.1	418.5	495.1	408.0	353.6	-21.6	117.7	-76.2	-644.9
Tax %	18.4	26.0	30.0	25.0	20.9	26.0	22.5	22.5	-4.7	21.3		
PAT	1309.8	1392.4	1341.9	1408.2	1586.7	1409.9	1336.8	1189.6	221.3	435.5	-69.1	96.8
Adjusted PAT	1306.3	1386.5	1335.8	1404.0	1581.2	1409.7	1330.5	1187.3	216.7	436.3		
No. of Equity Shares	83.4	83.4	83.4	83.4	83.4	83.4	83.4	83.4	83.4	83.4		
EPS (Diluted)	15.7	16.7	16.1	16.9	19.0	16.9	16.0	14.3	2.7	5.2		

Source: Company, ICICI Direct Research

Q1FY27 Earnings call highlights

US

- The management has guided that the US base business is expected to grow in double digits in FY27 adjusting for gRevlimid sales last year.
- Dr. Reddys has launched bosutinib tablets (400mg, brands annual sales of US\$ 300million) with 180 days exclusivity in US in Q1FY27.
- With regards to the generics tariff announcement, the company has supplies from CMOs account for nearly 25-30% of the US sales and company does not immediately plan to shift manufacturing base to US due to the tariff situation.


Other markets

- India business organic growth stood at 15.5% and Semaglutide was not a major contributor for base business growth.
- In Europe, NRT revenues declined primarily due to the change in operating model (now net of rebates and discount) post integration. This change in accounting policy had no major impact on product profitability.
- Growth in the RoW revenues was led by higher volumes, new product launches and currency.
- Growth in Russia was driven by price hikes in certain brands, new product launches and currency benefits.

Other Aspects

- The management expects Semaglutide supplies to resume in H2FY27 and the company is likely to seek PLI incentives from the Government for Semaglutide sales.
- The management has guided for EBITDA margins of ~20% in FY27 supported by the branded business.
- ETR for FY27 is guided to remain between 24-25%
- R&D spending is expected to be ~7-8% of sales in FY27.

- Semaglutide and Abatacept launches are expected to be margin accretive as most of the cost associated with the peptide and biosimilar business is already in the cost base.
- Dr. Reddys is likely to sell 6-7 million semaglutide pens between November 2026-March 2027 which was earlier expected to be 10-11 million.
- In Q1FY27, the company sold ~1,80,000 semaglutide pens in Canada and India.
- The management mentioned that Abatacept would be manufactured at Bachupally biologics plant and the goal date for the product is December 2026.
- Subcutaneous bAbatacept is likely to be launched in the US by end of FY28 and in H2FY29 in Europe

Exhibit 2: 2 year forward P/E Band


Source: Company, ICICI Direct Research

Exhibit 3: Top 10 brand performance for 3 years (in ₹ crore)

Brands	Rank	MAT JUN'23	MAT JUN'24	MAT JUN'25	MAT JUN'26	CAGR(MAT JUN'23-26)
ATARAX	1	197.9	210.5	243.2	274.0	11%
KETOROL	2	152.2	185.7	219.5	265.0	20%
ECONORM	3	187.6	193.7	230.9	248.7	10%
VOVERAN	4	240.5	250.1	235.4	237.3	0%
OMEZ	5	204.6	220.0	213.7	228.8	4%
HEXAXIM	6	123.9	152.8	180.2	226.3	22%
VENUSIA	7	112.2	142.1	167.2	197.5	21%
MENACTRA	8	90.7	126.5	156.1	189.9	28%
ZEDEX	9	139.9	128.8	157.9	179.4	9%
OMEZ D+	10	0.1	83.3	151.4	175.0	1105%

Source: IQVIA, ICICI Direct Research

Financial summary

Exhibit 4: Profit and loss statement

₹ crore

(Year-end March)	FY25	FY26	FY27E	FY28E
Revenues	32,648.0	33,700.2	34,335.2	39,364.2
Growth (%)	16.6	3.2	1.9	14.6
Raw Material Expenses	9,979.9	12,239.2	12,829.8	13,777.5
Employee expenses	5,580.0	5,990.9	7,001.2	6,888.7
Other expenses	8,606.2	8,664.8	8,891.7	10,234.7
Total Operating Expenditure	24,166.1	26,894.9	28,722.7	30,900.9
EBITDA	8,481.9	6,805.3	5,612.5	8,463.3
Growth (%)	7.0	-19.8	-17.5	50.8
Interest	282.8	373.8	502.0	386.7
Depreciation	1,704.2	2,410.6	2,147.9	2,229.3
PBT before Exceptional Items	7,661.8	5,379.3	4,471.8	6,634.6
Share of profit/ (loss) of equity accounted investees	-21.7	-13.4	0.0	0.0
PBT	7,683.5	5,392.7	4,471.8	6,634.6
Total Tax	1,954.3	1,235.1	1,058.0	1,569.7
PAT	5,729.2	4,157.6	3,413.8	5,064.9
Adjusted PAT	5,707.5	4,144.2	3,413.8	5,064.9
Growth (%)	2.6	-27.4	-17.6	48.4
EPS	68.7	49.9	40.9	60.7
EPS (Adjusted)	68.4	49.7	40.9	60.7

Source: Company, ICICI Direct Research

Exhibit 5: Cash flow statement

₹ crore

(Year-end March)	FY25	FY26	FY27E	FY28E
Profit/(Loss) after taxation	5,680.2	4,040.1	3,413.8	5,064.9
Add: Depreciation & Amortization	1,703.7	2,058.8	2,147.9	2,229.3
Net Increase in Current Assets	-2,303.6	-1,532.3	-1,182.6	-2,351.4
Net Increase in Current Liabilities	-695.3	457.7	434.4	534.6
CF from operating activities	4,642.8	5,673.7	5,315.5	5,864.1
(Inc)/dec in Fixed Assets	-3,388.6	-3,809.6	-2,220.0	-2,220.0
(Inc)/dec in Investments	2,511.8	-2,711.6	-780.0	-780.0
Others	-4,225.3	-28.1	-27.8	-28.9
CF from investing activities	-5,102.1	-6,549.3	-3,027.8	-3,028.9
Inc / (Dec) in Equity Capital	-119.6	39.7	0.0	0.0
Inc / (Dec) in Loan	2,319.6	1,899.4	0.0	0.0
Dividend & Dividend Tax	-666.2	-665.9	-667.2	-667.2
Others	-348.3	-444.1	-502.0	-386.7
CF from financing activities	1,185.5	829.1	-1,169.2	-1,053.9
Net Cash flow	726.2	-46.5	1,118.5	1,781.3
Opening Cash	710.7	1,465.4	1,536.8	2,655.3
Closing Cash	1,465.4	1,536.8	2,655.3	4,436.6
Free Cash Flow	1,254.2	1,864.1	3,095.5	3,644.1
FCF Yield	1.3%	2.0%	3.3%	3.9%

Source: Company, ICICI Direct Research

Exhibit 6: Balance sheet

₹ crore

(Year-end March)	FY25	FY26	FY27E	FY28E
Equity Capital	83.4	83.5	83.5	83.5
Net Network	33,466.2	37,808.0	40,554.6	44,952.4
Total Shareholders fund	33,549.6	37,891.5	40,638.1	45,035.9
Total Debt	4,676.6	7,734.1	7,734.1	7,734.1
Deferred Tax Liability	1,403.8	1,546.7	1,608.6	1,672.9
Other Non Current Liabilities	623.2	683.7	711.0	739.5
Long term Provisions	29.8	33.8	35.2	36.6
Source of Funds	40,283	47,890	50,727	55,219
Gross Block - Fixed Assets	33,001.4	39,083.1	40,653.1	42,223.1
Accumulated Depreciation	16,088.9	18,499.5	20,647.4	22,876.7
Net Block	16,912.5	20,583.6	20,005.7	19,346.4
Capital WIP	2,465.6	1,460.2	2,110.2	2,760.2
Net Fixed Assets	19,378.1	22,043.8	22,115.9	22,106.6
Goodwill	1,313.9	1,479.7	1,479.7	1,479.7
Investments	4,051.1	5,284.8	6,064.8	6,844.8
Inventory	7,108.5	7,653.4	8,436.1	9,059.2
Cash	1,465.4	1,536.8	2,655.3	4,436.6
Debtors	9,042.0	10,123.4	10,314.2	11,824.8
Loans & Advances & Other CA	3,076.7	5,230.5	5,439.7	5,657.3
Total Current Assets	21,687.4	26,356.0	28,657.2	32,789.8
Creditors	2,647.8	3,037.9	3,184.5	3,419.7
Provisions & Other CL	6,495.8	7,195.7	7,483.5	7,782.9
Total Current Liabilities	9,143.6	10,233.6	10,668.0	11,202.6
Net Current Assets	12,543.8	16,122.4	17,989.1	21,587.3
LT L& A, Other Assets	1,163.6	740.1	769.7	800.5
Deferred Tax Assets	1,832.5	2,219.0	2,307.8	2,400.1
Application of Funds	40,283	47,890	50,727	55,219

Source: Company, ICICI Direct Research

Exhibit 7: Key ratios

(Year-end March)	FY25	FY26	FY27E	FY28E
Per share data (₹)				
EPS	68.4	49.7	40.9	60.7
BV per share	402.3	454.3	487.3	540.0
Operating Ratios (%)				
Gross Profit Margins	69.4	63.7	62.6	65.0
EBITDA margins	26.0	20.2	16.3	21.5
Net Profit margins	17.5	12.3	9.9	12.9
Inventory days	260	228	240	240
Debtor days	101	110	110	110
Creditor days	97	91	91	91
Asset Turnover	1.0	0.9	0.8	0.9
EBITDA conversion Rate	54.7	83.4	94.7	69.3
Return Ratios (%)				
RoE	17.0	10.9	8.4	11.2
RoCE	18.4	10.0	7.6	12.9
RoIC	24.9	12.8	7.7	13.4
Valuation Ratios (x)				
P/E	16.5	22.7	27.6	18.6
EV / EBITDA	11.1	22.7	16.9	10.9
EV / Revenues	2.9	2.9	2.8	2.3
Market Cap / Revenues	2.9	2.8	2.7	2.4
Price to Book Value	2.8	2.5	2.3	2.1
Solvency Ratios				
Debt / Equity	0.1	0.2	0.2	0.2
Debt / EBITDA	0.6	1.1	1.4	0.9
Current Ratio	2.1	2.2	2.3	2.4
Quick Ratio	1.3	1.5	1.5	1.6
Working Capital Cycle	264	247	259	259

Source: Company, ICICI Direct Research

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%

Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research
Desk,
ICICI Securities Limited,
Third Floor, Brillanto
House,
Road No 13, MIDC,
Andheri (East)
Mumbai – 400 093
research@icicidirect.com

ANALYST CERTIFICATION

I/We, Siddhant Khandekar, Inter-CA; Shubh Mehta, MBA(Tech); Vedant Nilekar, MBA, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number –INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal

Contact number: 022-40701000 E-mail Address: complianceofficer@icicisecurities.com

For any queries or grievances: Mr. Jeetu Jawrani Email address: headservicequality@icicidirect.com Contact Number: 18601231122

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

ICICI Securities Limited has not used any Artificial Intelligence tools for preparation of this Research Report